Ultragenyx Dividends

The next dividend date for Ultragenyx has not yet been scheduled.

What is a Dividend Date

When we talk about a dividend date, we’re referring specifically to the ex-dividend date.

This is the date on which all stockholders will earn a dividend. Technically, a person needs to be the owner of a share of stock as of the night before the ex-dividend date in order to earn the dividend.

The ex-dividend date is different than the date when the dividend is issued. Although you earn a dividend on the ex-dividend date, that dividend is typically not disbursed to your account until several weeks later.

Most brokerages will automatically credit the dividend to your account once it’s issued.

Historical Dividends for Ultragenyx (RARE)

No Results.
DateDeclaration DateRecord DatePayment DateAmount
No Results.

More About Ultragenyx

Country
USA
Full Time Employees
1,294

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.

Owning Ultragenyx Stock on the Dividend Date

If you own Ultragenyx stock on the ex-dividend date, then you earn the associated dividend.

Theoretically, the price of Ultragenyx stock should go down by the amount of the dividend (in addition to any other pressures that market forces have on the price of Ultragenyx stock).

Therefore, it is typically not expected that there is any incremental profit to be gained from buying Ultragenyx stock right before the ex-dividend date and then selling it immediately after. It’s not like you get the Ultragenyx dividend payout for free just by doing that since there is typically an equivalent commensurate drop in the stock price.

Learning More Ultragenyx Dividends

You can contact us any time if you would like to ask questions about Ultragenyx dividends or anything else related to the stock market.